Analyst Naz Rahman from Maxim Group reiterated a Buy rating on Silexion Therapeutics (SLXN – Research Report) and keeping the price target at $9.00.
Naz Rahman has given his Buy rating due to a combination of factors surrounding Silexion Therapeutics’ promising developments with their drug, SIL-204. The company recently announced positive pre-clinical data from an orthotopic pancreatic cancer model, which closely mimics human pancreatic cancer. This data showed that systemic administration of SIL-204 significantly reduced tumor growth and metastasis, leading to a substantial increase in the company’s stock value.
The efficacy of SIL-204 was demonstrated across multiple pancreatic cancer cell lines, with notable reductions in tumor bioluminescence, indicating a decrease in tumor cell numbers. The study also highlighted SIL-204’s potential to reduce metastasis in secondary organs, which could expand its market opportunity by targeting metastatic pancreatic cancers. These findings validate the systemic administration strategy and suggest a broader application for SIL-204, enhancing its potential impact in the treatment of pancreatic cancer. Consequently, these promising results underpin Rahman’s Buy rating for Silexion Therapeutics.
SLXN’s price has also changed dramatically for the past six months – from $0.870 to $1.450, which is a 66.67% increase.
Questions or Comments about the article? Write to editor@tipranks.com